Novoteris, LLC Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of Its Thiolanox(R) Nitric Oxide for the Treatment of Cystic Fibrosis

GARDEN GROVE, Calif., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced today that both the US Food and Dru... Biopharmaceuticals, Drug Delivery, FDA Novoteris, Thiolanox, nitric oxide, Cystic Fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news